CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
53.85
+0.33 (0.62%)
Aug 10, 2026, 12:31 PM EDT - Market open
CRISPR Therapeutics AG Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 291.34 | 347.56 | 298.26 | 389.48 | 211.89 | 923.03 |
Short-Term Investments | 2,073 | 1,628 | 1,606 | 1,304 | 1,603 | 1,456 |
Cash & Short-Term Investments | 2,364 | 1,976 | 1,904 | 1,694 | 1,815 | 2,379 |
Cash Growth | 37.36% | 3.78% | 12.41% | -6.70% | -23.70% | 40.75% |
Accounts Receivable | - | - | 25 | 200 | - | 0.31 |
Other Current Assets | 7.42 | 9.84 | 8.31 | 14.39 | 37.71 | 38.08 |
Total Current Assets | 2,372 | 1,986 | 1,937 | 1,908 | 1,853 | 2,418 |
Net Property, Plant & Equipment | 233.66 | 247.58 | 277.55 | 305.94 | 320.56 | 312.04 |
Other Intangible Assets | - | - | - | 0.02 | 0.07 | 0.13 |
Long-Term Investments | - | - | - | 1.97 | 53.13 | - |
Other Long-Term Assets | 45.34 | 32 | 27.35 | 13.57 | 16.28 | 22.2 |
Total Assets | 2,651 | 2,265 | 2,242 | 2,230 | 2,243 | 2,752 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.31 | 11.14 | 14.71 | 38.15 | 27.43 | 14.82 |
Accrued Expenses | 70.77 | 90.52 | 41.52 | 45.77 | 77.82 | 91.73 |
Current Portion of Leases | 18.65 | 18.58 | 17.29 | 15.63 | 15.84 | 12.16 |
Unearned Revenue | 15.19 | 15.77 | 3.85 | 4.11 | - | 1.01 |
Other Current Liabilities | 16.98 | 13.11 | 10.42 | 5.14 | 0.02 | 0.17 |
Total Current Liabilities | 132.9 | 149.12 | 87.78 | 108.79 | 121.11 | 119.88 |
Long-Term Debt | 586.2 | - | - | - | - | - |
Long-Term Leases | 178.9 | 188.17 | 206.41 | 223.01 | 228.18 | 212.87 |
Other Long-Term Liabilities | 6.22 | 6.14 | 15.77 | 14.97 | 18.29 | 19.66 |
Total Long-Term Liabilities | 771.32 | 194.31 | 222.17 | 237.98 | 246.47 | 232.53 |
Total Liabilities | 904.22 | 343.43 | 309.95 | 346.77 | 367.58 | 352.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 3.13 | 3.09 | 2.7 | 2.5 | 2.44 | 2.39 |
Treasury Stock | -0.06 | -0.06 | -0.06 | -0.06 | -0.06 | -0.06 |
Additional Paid-in Capital | 3,910 | 3,862 | 3,294 | 2,878 | 2,735 | 2,598 |
Accumulated Other Comprehensive Income | -4.63 | 4.82 | 1.84 | 1.91 | -15.65 | -5.07 |
Retained Earnings | -2,162 | -1,948 | -1,366 | -999.7 | -846.09 | -195.92 |
Shareholders' Equity | 1,747 | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 |
Total Liabilities & Equity | 2,651 | 2,265 | 2,242 | 2,230 | 2,243 | 2,752 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 783.75 | 206.75 | 223.69 | 238.63 | 244.02 | 225.03 |
Net Cash (Debt) | 1,581 | 1,769 | 1,680 | 1,455 | 1,571 | 2,154 |
Net Cash Growth | 4.97% | 5.29% | 15.47% | -7.40% | -27.05% | 32.24% |
Net Cash Per Share | 16.68 | 19.67 | 19.92 | 18.37 | 20.21 | 26.79 |
Book Value | 1,747 | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 |
Book Value Per Share | 18.43 | 21.37 | 22.90 | 23.77 | 24.12 | 29.85 |
Tangible Book Value | 1,747 | 1,922 | 1,932 | 1,883 | 1,875 | 2,399 |
Tangible Book Value Per Share | 18.43 | 21.37 | 22.90 | 23.77 | 24.12 | 29.84 |